Price$3.36+0.17 (+5.33%)
01:30 PM07:45 PM
News · 26 weeks77+60%
2026-02-012026-07-26
Mix3090d
- Other12(40%)
- SEC Filings9(30%)
- Insider5(17%)
- Analyst3(10%)
- Earnings1(3%)
Latest news
25 items- INSIDERPresident Yerxa Benjamin R sold $22,064 worth of shares (7,429 units at $2.97), decreasing direct ownership by 1% to 704,106 units (SEC Form 4) to satisfy withholding tax4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Operating Officer Schachle Joseph K sold $13,653 worth of shares (4,644 units at $2.94), decreasing direct ownership by 2% to 291,440 units (SEC Form 4) (withholding tax)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Executive Officer Magrath George sold $27,926 worth of shares (9,475 units at $2.95), decreasing direct ownership by 0.54% to 1,731,869 units (SEC Form 4) to satisfy tax liability4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Financial Officer Gagnon Robert E. sold $22,942 worth of shares (7,783 units at $2.95), decreasing direct ownership by 1% to 584,375 units (SEC Form 4) to cover taxes4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SECSEC Form 144 filed by Opus Genetics Inc.144 - Opus Genetics, Inc. (0001228627) (Subject)
- SECSEC Form 144 filed by Opus Genetics Inc.144 - Opus Genetics, Inc. (0001228627) (Subject)
- PROpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 ResultsRESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs. Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present the data at the annual EURETINA Congress
- PROpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseSuccessful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study designFDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during reviewCompany expects to initiate Phase 3 dosing in 4Q 2026 RESEARCH TRIANGLE PARK, N.C., July 06, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) in a Type B Rare Disease Evidence Princi
- PROpus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® IndexesRESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000®, the Russell 2000® and the Russell Microcap® Indexes, effective when the U.S. market opens on June 29, 2026, as part of the June 2026 Russell indexes reconstitution. "We are pleased to be included in these Russell indexes, which provide validation of the progress we’re making in advancing our gene therapies for in
- ANALYSTRBC Capital Mkts initiated coverage on Opus Genetics with a new price targetRBC Capital Mkts initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00
- SECSEC Form EFFECT filed by Opus Genetics Inc.EFFECT - Opus Genetics, Inc. (0001228627) (Filer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- SECSEC Form S-3 filed by Opus Genetics Inc.S-3 - Opus Genetics, Inc. (0001228627) (Filer)
- ANALYSTGuggenheim initiated coverage on Opus Genetics with a new price targetGuggenheim initiated coverage of Opus Genetics with a rating of Buy and set a new price target of $16.00
- PROpus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease ExpertsRESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the guest speakers for its virtual Research & Development (R&D) Science Forum to be held on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET. The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics' multi-asset gene therapy pipeline, which is designed to address the underlying genetic causes of severe IRDs. The Forum will include deta
- PROpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the "Company"), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's 2021 Inducement Plan, as amended, as a material inducement to employment to ten non-executive employees who were not previously employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted in the form of options to
- PROpus Genetics to Present at the 2026 Jefferies Global Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET. A link to the live and archived webcast may be accessed on Opus Genetics' website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindne
- ANALYSTLeerink Partners initiated coverage on Opus Genetics with a new price targetLeerink Partners initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00
- INSIDERDirector Foundation Fighting Blindness Retinal Degeneration Fund sold $7,395,000 worth of shares (1,700,000 units at $4.35) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.SCHEDULE 13G/A - Opus Genetics, Inc. (0001228627) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.SCHEDULE 13G/A - Opus Genetics, Inc. (0001228627) (Subject)
- SECSEC Form S-8 filed by Opus Genetics Inc.S-8 - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 11:00 a.m. ET. A link to the live and archived webcast may be accessed on Opus Genetics' website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and preven
- SECSEC Form 10-Q filed by Opus Genetics Inc.10-Q - Opus Genetics, Inc. (0001228627) (Filer)
IRD FAQ
5 questionsWhere does IRD stock trade?
Opus Genetics Inc. (IRD) is listed on NASDAQ.What sector and industry is IRD in?
Opus Genetics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IRD?
Opus Genetics Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Outperform with a $1000.00 price target on 2026-06-23. Recent price targets range from $700.00 to $1600.00.What companies are similar to IRD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IRD side-by-side with any of them on Quantisnow.How can I track IRD on Quantisnow?
Quantisnow aggregates Opus Genetics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRD to receive live email and push alerts on every new disclosure.